FOLLOWUS
Effect of Poria cocos hydroethanolic extract on treating adriamycin-induced rat model of nephrotic syndrome
Effect of Poria cocos hydroethanolic extract on treating adriamycin-induced rat model of nephrotic syndrome
- 中国结合医学杂志（英文版） 2017年23卷第12期 页码：916-922
- Affiliations：
1. Provincial and the Ministry of Education Key Laboratory of Resource Science and Chinese Herbal Compound in Chinese Medicine, Hubei University of Chinese Medicine,Wuhan,China
2. Pharmacy Faculty, Hubei University of Chinese Medicine,Wuhan,China
- Author bio：
- Funds：Supported by the National Natural Science Foundation of China (No. 30970295) and Youth Fund Project of Hubei Provincial Department of Education (No. Q20091606), China
DOI：10.1007/s11655-016-2643-6
中图分类号：纸质出版日期：2017，
网络出版日期：2016-12-29，
Scan for full text
Zan, Jf., Shen, Cj., Zhang, Lp. et al. Effect of Poria cocos hydroethanolic extract on treating adriamycin-induced rat model of nephrotic syndrome., Chin. J. Integr. Med. 23, 916–922 (2017). https://doi.org/10.1007/s11655-016-2643-6
Jun-feng Zan, Chan-juan Shen, Li-ping Zhang, et al. Effect of Poria cocos hydroethanolic extract on treating adriamycin-induced rat model of nephrotic syndrome[J]. Chinese Journal of Integrative Medicine, 2017,23(12):916-922.
Zan, Jf., Shen, Cj., Zhang, Lp. et al. Effect of Poria cocos hydroethanolic extract on treating adriamycin-induced rat model of nephrotic syndrome., Chin. J. Integr. Med. 23, 916–922 (2017). https://doi.org/10.1007/s11655-016-2643-6 DOI：
Jun-feng Zan, Chan-juan Shen, Li-ping Zhang, et al. Effect of Poria cocos hydroethanolic extract on treating adriamycin-induced rat model of nephrotic syndrome[J]. Chinese Journal of Integrative Medicine, 2017,23(12):916-922. DOI： 10.1007/s11655-016-2643-6.
摘要
To evaluate the effect of Poria cocos (Schw.) Wolf hydroethanolic extract (PHE) against nephrotic syndrome (NS) in rats and to identify the potential active components from PHE. The high content compounds were isolated and purified by using column chromatography followed by preparative highperformance liquid chromatography (p-HPLC). Forty male Wistar rats with adriamycin (ADR)-induced NS were randomly divided into 5 groups
8 in each group: model control group
positive control group (with prednisone treatment)
PHE low-dose group
PHE middle-dose group and PHE high-dose group. Another 8 rats were recruited as vehicle control group. All rats received the intragastric administration of corresponding drugs or saline for 30 days. During the experimental period
rats' behavior and appearance were observed and recorded daily
and their body weights were recorded weekly. After treatment
24-h urine samples were collected to evaluate the urine protein and urine creatinine (Ucr); then the rats were sacrificed to collect carotid blood and to determine the levels of serum total protein (TP)
albumin (Alb)
globulin (Glo)
total cholesterol (TC) and cytokine interlukin-4 (IL-4). Six acidic components were isolated and identified from the PHE section: pachymic acid
15α-hydroxydehydrotumulosic acid
trametenolic acid
dehydropachymic acid
3β-hydroxy-lanosta-7
9(11)
24-trien-21-oic-acid and dehydroeburicoic acid. Compared with the model control group
the urine protein content were significantly decreased in the PHE treatment groups and positive control group (P<0.05)
especially PHE middle-dose group (P<0.01). The Ucr values and serum levels of TP
Glo
TC and IL-4 in PHE low- and middle-dose groups were also presented obvious recover tendency as compared with the model control group (P<0.05 or P<0.01). However
positive control group and all PHE groups indicated no significant therapeutic effect on raising Alb value
although PHE low- and middle-dose treatment groups showed better outcomes than positive control group (P>0.05). PHE showed an encouraging therapeutic effect against ADR-induced NS in a rat model. PHE might be a group of effective substances for the treatment of NS.
Abstract
To evaluate the effect of Poria cocos (Schw.) Wolf hydroethanolic extract (PHE) against nephrotic syndrome (NS) in rats and to identify the potential active components from PHE. The high content compounds were isolated and purified by using column chromatography followed by preparative highperformance liquid chromatography (p-HPLC). Forty male Wistar rats with adriamycin (ADR)-induced NS were randomly divided into 5 groups
8 in each group: model control group
positive control group (with prednisone treatment)
PHE low-dose group
PHE middle-dose group and PHE high-dose group. Another 8 rats were recruited as vehicle control group. All rats received the intragastric administration of corresponding drugs or saline for 30 days. During the experimental period
rats' behavior and appearance were observed and recorded daily
and their body weights were recorded weekly. After treatment
24-h urine samples were collected to evaluate the urine protein and urine creatinine (Ucr); then the rats were sacrificed to collect carotid blood and to determine the levels of serum total protein (TP)
albumin (Alb)
globulin (Glo)
total cholesterol (TC) and cytokine interlukin-4 (IL-4). Six acidic components were isolated and identified from the PHE section: pachymic acid
15α-hydroxydehydrotumulosic acid
trametenolic acid
dehydropachymic acid
3β-hydroxy-lanosta-7
9(11)
24-trien-21-oic-acid and dehydroeburicoic acid. Compared with the model control group
the urine protein content were significantly decreased in the PHE treatment groups and positive control group (P<0.05)
especially PHE middle-dose group (P<0.01). The Ucr values and serum levels of TP
Glo
TC and IL-4 in PHE low- and middle-dose groups were also presented obvious recover tendency as compared with the model control group (P<0.05 or P<0.01). However
positive control group and all PHE groups indicated no significant therapeutic effect on raising Alb value
although PHE low- and middle-dose treatment groups showed better outcomes than positive control group (P>0.05). PHE showed an encouraging therapeutic effect against ADR-induced NS in a rat model. PHE might be a group of effective substances for the treatment of NS.
关键词
Poria Cocoshydroethanolic extractNephrotic SyndromeChinese Medicine
Keywords
Poria Cocoshydroethanolic extractNephrotic SyndromeChinese Medicine
references
Barzilay Z, Paret G. The nephrotic syndrome. New Engl J Med 1998;339:773.
Haas M. The nephrotic syndrome. New Engl J Med 1998;339:772–773.
Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976–1979 and 1995–1997. Am J Kidney Dis 1997;30:621–631.
Hull RP, Goldsmith DJ. Nephrotic syndrome in adults. BMJ 2008;336:1185–1189.
Kuroki A, Akizawa T, Koshikawa S. Drug-induced nephrotic syndrome. Jpn J Clin Med 2007;65 (Suppl 8):563–566.
Orth SR, Ritz E. The nephrotic syndrome. New Engl J Med 1998;338:1202–1211.
Greenbaum LA, Benndorf R, Smoyer WE. Childhood nephrotic syndrome—current and future therapies. Nature Rev Nephrol 2012;8:445–458.
Goumenos DS, Ahuja M, Davlouros P, El Nahas AM, Brown CB. Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study. Clin Nephrol 2006;65:317–323.
van Husen M, Kemper MJ. New therapies in steroidsensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol 2011;26:881–892.
Brater DC. Resistance to loop diuretics. Why it happens and what to do about it? Drugs 1985;30:427–443.
Cody RJ. Clinical trials of diuretic therapy in heart failure: research directions and clinical considerations. J Am Coll Cardiol 1993;22:165A-171A.
Hille U, Soergel P, Makowski L, Dork-Bousset T, Hillemanns P. Lymphedema of the breast as a symptom of internal diseases or side effect of mTor inhibitors. Lymphat Res Biol 2012;10:63–73.
Le Roy V, Delmas Y, Verdoux H. Chronic renal complications induced by lithium. Encephale 2009;35:605–610.
Murray MD, Brater DC. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Ann Rev Pharmacol Toxicol 1993;33:435–465.
Schwarz A. New aspects of the treatment of nephrotic syndrome. J Am Soc Nephrol 2001;12 (Suppl 17):S44–S47.
Lee SM, Lee YJ, Yoon JJ, Kang DG, Lee HS. Effect of Poria cocos on hypertonic stress-induced water channel expression and apoptosis in renal collecting duct cells. J Ethnopharmacol 2012;141:368–376.
Li TH, Hou CC, Chang CL, Yang WC. Anti-hyperglycemic properties of crude extract and triterpenes from Poria cocos. Evid Based Complement Altern Med 2011;2011:128402.
Poon TY, Ong KL, Cheung BM. Review of the effects of the traditional Chinese medicine Rehmannia Six Formula on diabetes mellitus and its complications. J Diabetes 2011;3:184–200.
Sato M, Tai T, Nunoura Y, Yajima Y, Kawashima S, Tanaka K. Dehydrotrametenolic acid induces preadipocyte differentiation and sensitizes animal models of noninsulin-dependent diabetes mellitus to insulin. Biol Pharm Bull 2002;25:81–86.
Chen YY, Chang HM. Antiproliferative and differentiating effects of polysaccharide fraction from fu-ling (Poria cocos) on human leukemic U937 and HL-60 cells. Food Chem Toxicol 2004;42:759–769.
Esteban CI. Medicinal interest of Poria cocos (Wolfiporia extensa). Rev Iberoam Micol 2009;26:103–107.
Gao X, Zheng X, Li Z, Zhou Y, Sun H, Zhang L, et al. Metabonomic study on chronic unpredictable mild stress and intervention effects of Xiaoyaosan in rats using gas chromatography coupled with mass spectrometry. J Ethnopharmacol 2011;137:690–699.
Lee MR, Yun BS, Park SY, Ly SY, Kim SN, Han BH, et al. Anti-amnesic effect of Chong-Myung-Tang on scopolamineinduced memory impairments in mice. J Ethnopharmacol 2010;132:70–74.
Liu C, Gao P, Qian J, Yan W. Immunological study on the antitumor effects of fungus polysaccharides compounds. J Hygiene Res (Chin) 2000;29:178–180.
Chen X, Zhang L, Cheung PC. Immunopotentiation and antitumor activity of carboxymethylated-sulfatedβ- (1→3)-d-glucan from Poria cocos. Int Immunopharmacol 2010;10:398–405.
Rios JL. Chemical constituents and pharmacological properties of Poria cocos. Planta Med 2011;77:681–691.
Yu SJ, Tseng J. Fu-Ling, a Chinese herbal drug, modulates cytokine secretion by human peripheral blood monocytes. Int J Immunopharmacol 1996;18:37–44.
Zhang GW, Liu HY, Xia QM, Li JQ, Lu H, Zhang QH, et al. Anti-rejection effect of ethanol extract of Poria cocos wolf in rats after cardiac allograft implantation. Chin Med J 2004;117:932–935.
Zhang M, Chiu LC, Cheung PC, Ooi VE. Growth-inhibitory effects of a beta-glucan from the mycelium of Poria cocos on human breast carcinoma MCF-7 cells: cell-cycle arrest and apoptosis induction. Oncol Reports 2006;15:637–643.
Liu L. The experience of applying Fangji Fuling Decoction for the treatment of nephrotic syndrome. Chin J Ethnomed Ethnopharm (Chin) 2010;22:188.
Ji Z, Huang C, Liang C, Chen B, Chen S, Sun W. Protective effects of blocking renin-angiotensin system on the progression of renal injury in glomerulosclerosis. Cell Mol Immunol 2005;2:150–154.
Korzets Z, Pomeranz A, Golan E, Bernheim J. Pefloxacin in adriamycin induced nephrotic syndrome in the rat. Nephrol Dial Transplant 1997;12:286–288.
Lebrecht D, Setzer B, Rohrbach R, Walker UA. Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis. Nephrol Dial Transplant 2004;19:329–336.
Kramer A, van den Hoven M, Rops A, Wijnhoven T, van den Heuvel L, Lensen J, et al. Induction of glomerular heparanase expression in rats with adriamycin nephropathy is regulated by reactive oxygen species and the reninangiotensin system. J Am Soc Nephrol 2006;17:2513–2520.
Lin JJ, Yang Y, Gao N, Fan ZQ. Doxorubicin Injection time and dose the influence of nephrotic syndrome model. Chin J Integr Tradit West Nephrol (Chin) 2011;12:676–678.
Zhang Y, Zhang P, Ning HY, Guo YL, Xing GQ, Shen W. Establishment of a rat model of nephrosis induced by single tail vein injection of doxorubicin. Acta Lab Anim Sci Sin (Chin) 2013;21:1–4.
Somlo S, Mundel P. Getting a foothold in nephrotic syndrome. Nat Genet 2000;24:333–335.
Kramer AB, Bos H, van Goor H, Navis GJ. Sodium intake modifies the negative prognostic value of renal damage prior to treatment with ACE inhibitors on proteinuria induced by adriamycin. Nephr Physiol 2006;103:43–52.
Wong CK, Ho CY, Li EK, Lam CW. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000;9:589–593.
Lu YF, Xie CX, Xu Yh, Chen TH. The effect of warming yang to promote blood circulation-WYRT on the levels of IL-4 and IgE in nephrotic rat induced by adriamycin-induced nephrotic syndrome. Chin J Integr Tradit West Nephrol (Chin) 2003;4:77–78.
Furusu A, Miyazaki M, Koji T, Abe K, Ozono Y, Harada T, et al. Involvement of IL-4 in human glomerulonephritis: an in situ hybridization study of IL-4 mRNA and IL-4 receptor mRNA. J Am Soc Nephrol 1997;8:730–741.
Fan XZ, Li H, Liu WF, Zhao JQ. Change of serum levels of IL-4 and IL-10 in patients with nephrotic syndrome and its clinical significance. Immunol J 2010;26:56–62.
0
浏览量
0
Downloads
3
CSCD
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 邮编：100091
- 联系电话：010-62886827, 62877592 传真：010-62874291
- 技术支持由北京北大方正电子有限公司提供 京ICP备05067934号-1
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
